Type 1 diabetes research partnership provided with another 3 million GBP

A research partnership between the United Kingdom and Israel has received a further £3m of funding.
The partnership, known as BIRAX (British Israeli Research Academic Exchange) addresses a number of health conditions, with significant attention being directed towards type 1 diabetes.
“Regenerative medicine is a thrilling frontier for type 1 diabetes research that offers the potential to change lives,” said Clare McVicker, Director of Research Advocacy at JDRF UK.
“JDRF is delighted that BIRAX is successfully strengthening international research collaboration between Israel and Britai, and we are delighted to once again be a part of this project.”
The extra funding has been allocated in addition to the millions already given to the projects, which aim to find cures for type 1 diabetes, heart disease, Parkinson’s disease, multiple sclerosis and liver disease, many of which can also occur as complications of diabetes.
The researchers are aiming to cure type 1 diabetes through “regenerative” procedures, which focus on restoring the function of currently defunct insulin-producing beta cells in the pancreas.
Alan Gemmell, Director of the British Council in Israel, commented: “Through Birax, the best scientists in Britain and Israel are working together to develop therapies and find cures for diseases that affect millions of people. We’re proud to be able to support labs across the UK and fund their work through partnerships with world-leading medical research foundations.”